

## **Local-regional management after neoadjuvant therapy**

Laura S Dominici, M.D., FACS

Dana-Farber/Brigham Cancer Center

Section Chief of Breast Surgery, Brigham and Women's Faulkner Hospital

Chair, Dana-Farber/Brigham Cancer Committee

Associate Professor of Surgery, Harvard Medical School

Boston, MA, U.S.A.

Neoadjuvant systemic therapy is frequently recommended for patients with both advanced and early breast cancers. Surgical decision making can be different for patients receiving neoadjuvant therapy. There are considerations around decisions for breast conservation versus mastectomy and axillary management that are impacted by receipt of and response to neoadjuvant therapy. We will discuss these complex issues, evidence for current management, and future directions.